Physician profile
Molly B Sharp
NPI 1922257088
$5,115.94
in general payments reported to CMS, 2019-2025
18 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,421 · 2022: $1,045 · 2023: $877 · 2024: $329 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.82 |
| Education | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,303.67 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $952.98 | 2021-2025 | |
| Lundbeck LLC | $840.14 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $383.54 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $315.10 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $288.84 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.03 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $157.40 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $132.29 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $107.96 | 2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $92.41 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $82.44 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $62.15 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $36.80 | 2021 | |
| Eisai INC. | $36.71 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $27.46 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $24.80 | 2025 | Jornay Pm |
| Allergan, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.